Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NI-1801 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Lightchain Bioscience
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
NI-1801 is a bispecific monoclonal antibody that targets both CD47 and mesothelin. By binding to CD47, it blocks the interaction with signal regulatory protein alpha (SIRPalpha), an inhibitory protein on macrophages, thereby promoting phagocytosis of tumor cells. The mesothelin targeting component directs the antibody to tumors expressing this antigen. Paclitaxel is a small molecule chemotherapeutic agent classified as a taxane; it stabilizes microtubules and prevents their depolymerization, disrupting mitosis and leading to cell death. The combination of NI-1801 with paclitaxel is being investigated for enhanced antitumor activity in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin[3][5][6].
- Brand names
- None
- Other names
- anti-CD47/anti-mesothelin bispecific antibody NI-1801Taxol (for paclitaxel)
02
Targets
MesothelinMicrotubuleCD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on NI-1801 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NI-1801 + paclitaxel.